摘要
Abstract
Objective To evaluate the efficacy and safety of repaglinide,a kind of oral hypoglycemic agent, in the treatment of type 2 diabetes. Methods Recent published papers that chose randomized comparative trials to distinguish clinical effects between repaglinide and gliclazide were collected for meta-analysis. Results Total seven papers met this requirement and were selected for meta-analysis. When fixed effects model was adopted for fasting plasma glucose ( FPG) analysis, results showed that Z = 0. 28, P = 0. 78 , WMD = 0. 04 ( - 0. 25,0. 34). When random effects model was adopted for 2h postprandial blood glucose (PBG) analysis, results showed that Z = 5. 54, P <0. 00001, WMD = -1.91 ( -2.58, -1.23). When fixed effects model was adopted for HbAIC analysis, results showed that Z = 1. 33, P = 0. 18, WMD = -0. 19( -0.47, -0.09). When fixed effects model was adopted for hypoglycemia analysis, results showed that Z = 3. 63, P = 0. 0003 , WMD = 0. 24 (0. 11 , 0. 52 ). Conclusion There is no significant difference between repaglinide and gliclazide in decreasing the levels of FPG and HbAlC. However, repaglinide could further decrease the level of 2 h PBG and prevent against hypoglycemia compared with gliclazide.关键词
瑞格列奈/格列齐特/2型糖尿病/空腹血糖/餐后2小时血糖/糖化血红蛋白/低血糖/随机对照试验/Meta分析Key words
repaglinide/gliclazide/type 2 diabetes/FPG/2 h PBG/HbAlC/hypoglycemia/randomized comparative trials/meta-analysis分类
医药卫生
